{3-(3,4-dimethoxyphenyl)-5-[4-(dimethylamino)phenyl]-4,5-dihydro-1H-pyrazol-1-yl}(phenyl)methanone

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: {3-(3,4-dimethoxyphenyl)-5-[4-(dimethylamino)phenyl]-4,5-dihydro-1H-pyrazol-1-yl}(phenyl)methanone
• 英文别名: [5-(3,4-dimethoxyphenyl)-3-[4-(dimethylamino)phenyl]-3,4-dihydropyrazol-2-yl]-phenylmethanone
• 化学式: C₂₆H₂₇N₃O₃
• 分子量: 429.5
• InChiKey: FVAXLNLKTOJRHJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  32
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  54.4
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• ARYL-SUBSTITUTED HETEROCYCLIC PDE4 INHIBITORS AS ANTI-INFLAMMATORY AGENTS
  申请人：Govek Steven P.

  公开号：US20100105729A1

  公开（公告）日：2010-04-29

  Disclosed herein are potent and selective aryl-substituted heterocyclic compounds, useful as inhibitors of phosphodiesterase 4 (PDE4), compositions comprising the same, and their application as pharmaceuticals for the treatment of disease. Methods of inhibition of PDE4 activity are also provided, as well as methods for the treatment of inflammatory diseases and other diseases in which PDE4 or one of its isoforms may play a role.
• [EN] ARYL-SUBSTITUTED HETEROCYCLIC INHIBITORS OF PDE4<br/>[FR] INHIBITEURS HÉTÉROCYCLIQUES DE PDE4 ARYL-SUBSTITUÉS
  申请人：KALYPSYS INC

  公开号：WO2008045663A2

  公开（公告）日：2008-04-17

  [EN] Disclosed herein are potent and selective aryl-substituted heterocyclic compounds, useful as inhibitors of phosphodiesterase 4 (PDE4), compositions comprising the same, and their application as pharmaceuticals for the treatment of disease. Methods of inhibition of PDE4 activity are also provided, as well as methods for the treatment of inflammatory diseases and other diseases in which PDE4 or one of its isoforms may play a role.
  [FR] L'invention concerne des composés hétérocycliques aryl-substitués puissants et sélectifs, servant d'inhibiteurs de la phosphodiestérase 4 (PDE4), des compositions comprenant ces composés, et leur application en tant que substances pharmaceutiques destinées à traiter des maladies. L'invention concerne également des procédés d'inhibition de l'activité de PDE4, ainsi que des procédés visant à traiter des maladies inflammatoires ou d'autres maladies dans lesquelles PDE4 ou l'un de ses isoformes peut jouer un rôle.